BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:enicepatide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of enicepatide\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07626515-159@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270408
DTEND;VALUE=DATE:20270409
SUMMARY:enicepatide: Phase 1 readout est. (NCT07626515)
DESCRIPTION:enicepatide\, phase 1.\nStudy: A Study to Evaluate Safety\, Tol
 erability\, and Pharmacokinetics of Enicepatide in Generally Healthy Adult
  Chinese Participants\nEstimated primary completion: 8 April 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/enicepatide#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07626515
URL:https://assetmemo.bio/drug/enicepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07589686-159@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271112
DTEND;VALUE=DATE:20271113
SUMMARY:enicepatide: Phase 2 readout est. (NCT07589686)
DESCRIPTION:enicepatide\, phase 2\, Obesity.\nStudy: A Dose-Finding Study o
 f Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Over
 weight\nEstimated primary completion: 12 November 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/enicepatide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07589686
URL:https://assetmemo.bio/drug/enicepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07670416-159@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280224
DTEND;VALUE=DATE:20280225
SUMMARY:enicepatide: Phase 3 readout est. (NCT07670416)
DESCRIPTION:enicepatide\, phase 3\, Obesity.\nStudy: A Study to Evaluate th
 e Effects of Enicepatide in Participants With Obesity or Overweight\, With
  or Without Type 2 Diabetes\nEstimated primary completion: 24 February 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/enicepatide#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07670416
URL:https://assetmemo.bio/drug/enicepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07351045-159@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280724
DTEND;VALUE=DATE:20280725
SUMMARY:enicepatide: Phase 3 readout est. (NCT07351045)
DESCRIPTION:enicepatide\, phase 3\, Obesity.\nStudy: A Clinical Study to Ev
 aluate the Effects of Enicepatide (RO7795068) in Participants With Obesity
  or Overweight Without Type 2 Diabetes\nEstimated primary completion: 24 J
 uly 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enicepatide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073
 51045
URL:https://assetmemo.bio/drug/enicepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07351058-159@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280807
DTEND;VALUE=DATE:20280808
SUMMARY:enicepatide: Phase 3 readout est. (NCT07351058)
DESCRIPTION:enicepatide\, phase 3\, Obesity.\nStudy: A Clinical Study to Ev
 aluate the Effects of Enicepatide (RO7795068) in Participants With Obesity
  or Overweight and Type 2 Diabetes\nEstimated primary completion: 7 August
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/enicepatide#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073510
 58
URL:https://assetmemo.bio/drug/enicepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07889648-159@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290402
DTEND;VALUE=DATE:20290403
SUMMARY:enicepatide: Phase 3 readout est. (NCT07889648)
DESCRIPTION:enicepatide\, phase 3\, Type 2 Diabetes.\nStudy: A Clinical Stu
 dy to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participan
 ts With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose
 -Lowering Medications\nEstimated primary completion: 2 April 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/enicepatide#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07889648
URL:https://assetmemo.bio/drug/enicepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07918846-159@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20310320
DTEND;VALUE=DATE:20310321
SUMMARY:enicepatide: Phase 3 readout est. (NCT07918846)
DESCRIPTION:enicepatide\, phase 3\, Obesity.\nStudy: A Clinical Study Testi
 ng Enicepatide in Participants Living With Overweight or Obesity and Cardi
 ovascular Disease\nEstimated primary completion: 20 March 2031. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/enicepatide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07918846
URL:https://assetmemo.bio/drug/enicepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
